cAHRmeleon Bioscience GmbH is an innovative new biotech spin-off of the German Cancer Research Center (DKFZ) in Heidelberg, Germany. cAHRmeleon is led by a highly motivated multi-disciplinary team of scientists with several decades of combined experience in immuno-oncology and cancer metabolism. We developed an AI-assisted and multi-omics-based discovery platform based on the Aryl Hydrocarbon Receptor (AHR), AI-AHR technology. Our technology enables the identification of AHR-modulators and the analysis of AHR-mediated biological functions promoting tumor immune evasion across diverse cancer types and in response to cancer immunotherapies, which led to:

1. Identifying IL4I1 as a novel drug target that activates the AHR and leads to immune suppression.

2. Creating AHR-profiles of patient samples showing diverse survival outcomes to establish prognostic and predictive assays in cancer.

Our strategy is to combine our AI- multi-omics excellence with experimental and clinical validation to identify new drug targets, accelerate cancer drug development, and develop companion diagnostics and prognostic tests.